Direct measurement of in vivo BCR::ABL1 kinase inhibition reveals stronger potency of asciminib as compared with imatinib and nilotinib
Open Access
- 11 June 2026
- journal article
- Published by Springer Nature in Leukemia
- Vol. 40 (7) , 1579-1582
Abstract
No abstract availableKeywords
Funding Information
- National Health and Medical Research Council (APP1135949)
- National Health and Medical Research Council (APP1117718)
- National Health and Medical Research Council (APP1138935)
- National Health and Medical Research Council (APP1027531)
This publication has 15 references indexed in Scilit:
- CML With Mutant ASXL1 Showed Decreased Sensitivity to TKI Treatment via Upregulation of the ALOX5‐BLTR Signaling PathwayCancer Science, 2025
- Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND studyBlood, 2024
- Asciminib in Newly Diagnosed Chronic Myeloid LeukemiaNew England Journal of Medicine, 2024
- Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up resultsLeukemia, 2024
- Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinibBlood Cancer Journal, 2023
- Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemiaBlood Cancer Journal, 2022
- ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemiaLeukemia, 2022
- Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemiaBlood, 2021
- European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemiaLeukemia, 2020
- BCR‐ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemiaBritish Journal of Haematology, 2010